The nation of Zimbabwe has rejected a major US healthcare agreement worth $367m (272 million pounds) spanning five years due to Washington's demand for sensitive data.
This rejection was revealed following a government memo dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
A government representative later explained that the United States was seeking genetic material for scientific study and profit while was not willing to share the resulting advantages from any future medical innovations.
"We will now turn to the challenging and unfortunate process of ending our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further negotiations to reach a agreement acceptable to all parties so the nation's critical HIV treatment initiative can be sustained.
Wider Context
This development follows a similar situation in Kenya, where a court blocked a similar health funding agreement following legal challenges were filed about the security of citizens' health data.
After returning to office recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral agreements to enhance openness and responsibility.
According to reports, 16 nations in Africa have so far signed similar health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy via US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data indefinitely, with no equivalent assurance of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," he stated.
"Effectively, our nation would provide the basic resources for medical research with no certainty that the resulting innovations would be accessible to our population should a future health crisis emerge."
National Interest and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of bilateral deals were disrupting systems previously set up via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage potential global health emergencies.
"This mechanism is designed to ensure that when a country contributes its information, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our US partners on how future co-operation might be structured in a manner that honours the independence and interests of each country."
Health Experts Response
A leading public health body said it recognised the official position, but urged that negotiations should continue given that much of the country's Aids initiatives relied on foreign aid.
"Where specific concerns exist, such as those involving information security or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," it commented.
The halted deal emphasises the complex challenges between receiving crucial foreign assistance and protecting national sovereignty in an ever more data-driven world.